| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10001782 | HBV | ENSG00000105851.11 | protein_coding | PIK3CG | Yes | No | 5294 | P48736 |
| TVIS10023515 | HBV | ENSG00000105851.11 | protein_coding | PIK3CG | Yes | No | 5294 | P48736 |
| TVIS10030913 | HBV | ENSG00000105851.11 | protein_coding | PIK3CG | Yes | No | 5294 | P48736 |
| TVIS30013925 | HIV | ENSG00000105851.11 | protein_coding | PIK3CG | Yes | No | 5294 | P48736 |
| TVIS30020890 | HIV | ENSG00000105851.11 | protein_coding | PIK3CG | Yes | No | 5294 | P48736 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PIK3CG |
|---|---|
| DrugBank ID | DB12483 |
| Drug Name | Copanlisib |
| Target ID | BE0001315 |
| UniProt ID | P48736 |
| Regulation Type | inhibitor |
| PubMed IDs | 29127587; 30147333 |
| Citations | Markham A: Copanlisib: First Global Approval. Drugs. 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6.@@Mensah FA, Blaize JP, Bryan LJ: Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 2018 Aug 13;11:4817-4827. doi: 10.2147/OTT.S142264. eCollection 2018. |
| Groups | Approved; Investigational |
| Direct Classification | Quinazolinamines |
| SMILES | COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3218576 |
